Drs. H. Jack West, Matthew Gubens, and Jyoti Patel, gathered post ASCO 2017 to discuss new information regarding lung cancer. In this video, the doctors discuss Improved Progression-Free Survival with Iressa as Adjuvant Therapy for EGFR Mutation Positive Patients.

Last year, an article came out in the Journal of Clinical Oncology that noted a gradual shift away from the "hard endpoint" of overall survival (OS) for lung cancer trials toward progression-free survival (PFS), a "softer endpoint" that is much more subject to interpretation.